Allogene Therapeutics Look to First Autoimmune CAR T Data in 4Q

Allogene Therapeutics (ALLO) reported 1Q26 earnings and provided updates on its key CAR T programs, noting strong interim MRD clearance for cema-cel and rescheduling ALLO-329 autoimmune data for 4Q26.

Key Takeaways

• 1.ALLO reported a 41.6% improvement in MRD clearance for cema-cel in the ALPHA3 study, significantly exceeding the management's 25-30% bar.
• 2.Initial data for the autoimmune candidate ALLO-329 is now expected in 4Q26, with maturity across multiple dose levels.
• 3.The company maintains a strong cash position of approximately $467mn (including recent offering proceeds), providing a runway into 1Q29.

Table of Contents

• Allogene Therapeutics Inc. (ALLO): Look to first autoimmune CAR T data in 4Q, as the registrational lymphoma study progresses
• Strong interim/futility cema-cel data supports ALPHA3 study success, with interim EFS data in mid-27
• First ALLO-329 data from the Ph1 RESOLUTION trial in autoimmune disease is now coming in 4Q
• 1Q26 EPS vs. GSe
• Valuation and Risks
• Disclosure Appendix
• Disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial